A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

NCT03075527 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped Criteria not met for second stage at time of interim analysis

Conditions

Mesothelioma

Interventions

DRUG: Tremelimumab
DRUG: Durvalumab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]